HER2 Circulating Tumor Cells in Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

HER2 Circulating Tumor Cells in Gastric Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01299688
• Other study ID #: 2009-12-008
• Status: Completed
• Phase: N/A
• First received: February 17, 2011
• Last updated: January 15, 2018
• Start date: March 2010
• Est. completion date: March 11, 2013

Study information

• Verified date: January 2018
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer.

Description:

We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be collected from metastatic gastric cancer patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 135
• Est. completion date: March 11, 2013
• Est. primary completion date: March 11, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients older than 18 years ? Patients with localized, histologically confirmed gastric cancer ? Informed consent form

Exclusion Criteria:

• No informed consent form

Related Conditions & MeSH terms

• Gastric Cancer
• Neoplastic Cells, Circulating
• Stomach Neoplasms

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To survey the frequency of HER2(+) CTC in gastric cancer		24month